US 2025/0019431 A1Published application

Kidney targeted immunotolerance

AssigneePandion Operations, Inc.

InventorsBridget LARKIN, Bilian LI, Nathan HIGGINSON-SCOTT, Kevin Lewis OTIPOBY, Joanne L. VINEY

Life of this patent

Estimating the term…

Abstract

Methods and compounds for conferring kidney-specific immune privilege.

Claims33

Dependent claims

A comprising a kidney targeting moiety, wherein the kidney targeting moiety comprises an anti-CDH16 antibody or an anti-OCT 2 antibody and an effector binding/modulating moiety, wherein the effector binding/modulating moiety is a PD-1 agonist, a CD39 Effector Domain, or an IL-2 mutein polypeptide (IL-2 mutein).

Dependencies are inferred from the claim text.

Facts

Application: 18/248,398Filed 15 Oct 2021
Priority: 16 Oct 2020
Published: 16 Jan 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 16/28
Against material from animals or humans: against receptors, cell surface antigens or cell surface determinants
C07K 16/468
Hybrid immunoglobulins: immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
A61P 13/12
Drugs for disorders of the urinary system: of the kidneys
A61P 37/06
Immunomodulators: immunosuppressants, e.g. drugs for graft rejection

Family

Application63/092,793Us provisional application · filed 16 Oct 2020
Application63/156,053Us provisional application · filed 3 Mar 2021
Application63/175,857Us provisional application · filed 16 Apr 2021
US 2025/0019431 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results